DEXCOM INC 10-Q

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Purchases of Equity Securities by the Issuer The following table provides information about purchases by the Company of its shares of common stock during the three-month period ended September 30, 2022: Period Total number of shares purchased (1) Average price paid per share Total number of shares purchased as part of publicly announced program (1) Maximum dollar value of shares that may yet to be purchased under the program (1) (in millions) 7/01/2022 - 7/31/2022 — — — $ 700.0 8/01/2022 - 8/31/2022 (2) 6,559,178 $ 85.03 6,559,178 $ 142.3 9/01/2022 - 9/30/2022 — — — $ 142.3 (1) On July 28, 2022, we announced that a duly authorized committee of our Board of Directors authorized and approved a share repurchase program of up to $700.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2023. (2) On August 1, 2022, we entered into an accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association (“JP Morgan”) to purchase $700.0 million of our outstanding common stock. In exchange for an upfront payment of $700.0 million, JPMorgan initially delivered approximately 3.0 million shares. The repurchases under the ASR agreement concluded on August 31, 2022, and we repurchased a total of approximately 6.6 million shares at an average price of $85.03 per share. See Note 8, “Stockholders’ Equity,” to the consolidated financial statements in Part 1, Item 1 of this Quarterly Report for additional information on the ASR Agreement and the transactions thereunder. ITEM 3 - DEFAULTS UPON SENIOR SECURITIES None. ITEM 4 - MINE SAFETY DISCLOSURES None.